์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck

219007

Caspase Inhibitor VI

Z-VAD-FMK, CAS 161401-82-7, is an irreversible pan caspase inhibitor. Does not require pretreatment with esterase for in vitro studies.

๋™์˜์–ด(๋“ค):

Caspase Inhibitor VI, Z-VAD-FMK

์กฐ์ง ๋ฐ ๊ณ„์•ฝ ๊ฐ€๊ฒฉ์„ ๋ณด๋ ค๋ฉด ๋กœ๊ทธ์ธ๋ฅผ ํด๋ฆญํ•ฉ๋‹ˆ๋‹ค.

ํฌ๊ธฐ ์„ ํƒ

์ œํ’ˆ์ •๋ณด (DICE ๋ฐฐ์†ก ์‹œ ๋น„์šฉ ๋ณ„๋„)

์‹คํ—˜์‹(Hill ํ‘œ๊ธฐ๋ฒ•):
C21H28FN3O7
CAS ๋ฒˆํ˜ธ:
161401-82-7
Molecular Weight:
453.46
MDL number:
MFCD03452883
UNSPSC Code:
12352200
NACRES:
NA.54
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100
Storage condition:
OK to freeze
desiccated

์ฃผ์š” ๋ฌธ์„œ

๋ชจ๋“  ๋ฌธ์„œ ๋ณด๊ธฐ
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜

์ œํ’ˆ ์ด๋ฆ„

Caspase Inhibitor VI, Z-VAD-FMK, CAS 161401-82-7, is an irreversible pan caspase inhibitor. Does not require pretreatment with esterase for in vitro studies.

SMILES string

FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C)C)CC(=O)O

InChI

1S/C21H28FN3O7/c1-12(2)18(25-21(31)32-11-14-7-5-4-6-8-14)20(30)23-13(3)19(29)24-15(9-17(27)28)16(26)10-22/h4-8,12-13,15,18H,9-11H2,1-3H3,(H,23,30)(H,24,29)(H,25,31)(H,27,28)/t13-,15-,18-/m0/s1

InChI key

SUUHZYLYARUNIA-YEWWUXTCSA-N

assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochemยฎ

storage condition

OK to freeze
desiccated

color

off-white

solubility

DMSO: 9 mg/mL

shipped in

ambient

storage temp.

−20ยฐC

Quality Level

100

๊ด€๋ จ ์นดํ…Œ๊ณ ๋ฆฌ

Biochem/physiol Actions

Cell permeable: no
Product does not compete with ATP.
Reversible: no

Disclaimer

Toxicity: Standard Handling (A)

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

General description

An irreversible general caspase inhibitor. Useful for studies involving recombinant, isolated, and purified caspase enzymes. Unlike Caspase Inhibitor I (Cat. No. 627610 ), this inhibitor does not require pretreatment with esterase for in vitro studies. A 10 mM (1 mg/221 ยตl) solution of Caspase Inhibitor VI (Cat. No. 219011 ) in DMSO is also available.

์ €์žฅ ๋“ฑ๊ธ‰

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

์‹œํ—˜ ์„ฑ์ ์„œ(COA)

์ œํ’ˆ์˜ ๋กœํŠธ/๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋ฅผ ์ž…๋ ฅํ•˜์—ฌ ์‹œํ—˜ ์„ฑ์ ์„œ(COA)์„ ๊ฒ€์ƒ‰ํ•˜์‹ญ์‹œ์˜ค. ๋กœํŠธ ๋ฐ ๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋Š” ์ œํ’ˆ ๋ผ๋ฒจ์— ์žˆ๋Š” โ€˜๋กœํŠธโ€™ ๋˜๋Š” โ€˜๋ฐฐ์น˜โ€™๋ผ๋Š” ์šฉ์–ด ๋’ค์—์„œ ์ฐพ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์ด ์ œํ’ˆ์„ ์ด๋ฏธ ๊ฐ€์ง€๊ณ  ๊ณ„์‹ญ๋‹ˆ๊นŒ?

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์—์„œ ์ตœ๊ทผ์— ๊ตฌ๋งคํ•œ ์ œํ’ˆ์— ๋Œ€ํ•œ ๋ฌธ์„œ๋ฅผ ์ฐพ์•„๋ณด์„ธ์š”.

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ ๋ฐฉ๋ฌธ

Chiara Brignola et al.
Antioxidants (Basel, Switzerland), 13(7) (2024-07-27)
Despite advancements in therapeutic strategies, the development of drug resistance and metastasis remains a serious concern for the efficacy of chemotherapy against colorectal cancer (CRC). We have previously demonstrated that low expression of ribosomal protein uL3 positively correlates with chemoresistance
Wayne A Cabral et al.
Aging cell, 20(9), e13457-e13457 (2021-08-29)
Hutchinson-Gilford progeria syndrome (HGPS) is a rare accelerated aging disorder most notably characterized by cardiovascular disease and premature death from myocardial infarction or stroke. The majority of cases are caused by a de novo single nucleotide mutation in the LMNA
Xiaoqing Qian et al.
Journal of cellular physiology, 236(7), 5235-5252 (2020-12-29)
Intratympanic injection of gentamicin has proven to be an effective therapy for intractable vestibular dysfunction. However, most studies to date have focused on the cochlea, so little is known about the distribution and uptake of gentamicin by the counterpart of
Amphipathic barbiturates as marine product mimics with cytolytic and immunogenic effects on head and neck squamous cell carcinoma cell lines.
von Hofsten, et al.
Frontiers in Pharmacology, 14, 1141669-1141669 (2023)
Takashi Kojima et al.
Disease models & mechanisms, 14(11) (2021-10-09)
KCNQ4 encodes the homotetrameric voltage-dependent potassium ion channel Kv7.4, and is the causative gene for autosomal dominant nonsyndromic sensorineural hearing loss, DFNA2. Dominant-negative inhibition accounts for the observed dominant inheritance of many DFNA2-associated KCNQ4 variants. In addition, haploinsufficiency has been
๋ชจ๋“  ๊ด€๋ จ๋œ ์„œ๋ฅ˜ ๋ณด๊ธฐ

๊ด€๋ จ ์ฝ˜ํ…์ธ 

๊ตญ์ œ ๋ฌด์—ญ ํ’ˆ๋ชฉ ๋ฒˆํ˜ธ

SKUGTIN
219007-1MGCN07790788048648
219007-250UGCN04055977202021

์ž์‚ฌ์˜ ๊ณผํ•™์žํŒ€์€ ์ƒ๋ช… ๊ณผํ•™, ์žฌ๋ฃŒ ๊ณผํ•™, ํ™”ํ•™ ํ•ฉ์„ฑ, ํฌ๋กœ๋งˆํ† ๊ทธ๋ž˜ํ”ผ, ๋ถ„์„ ๋ฐ ๊ธฐํƒ€ ๋งŽ์€ ์˜์—ญ์„ ํฌํ•จํ•œ ๋ชจ๋“  ๊ณผํ•™ ๋ถ„์•ผ์— ๊ฒฝํ—˜์ด ์žˆ์Šต๋‹ˆ๋‹ค..

๊ณ ๊ฐ์ง€์›ํŒ€์œผ๋กœ ์—ฐ๋ฝ๋ฐ”๋ž๋‹ˆ๋‹ค.